Drug · CHEMBL652
FLECAINIDE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. FLECAINIDE. Drugs and targets, record CHEMBL652. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL652
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| SCN5A | Sodium channel protein type 5 subunit alpha | Sodium channel protein type V alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6331 |
Source ChEMBL
Diseases18
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| atrial fibrillation | Phase 3 | ClinicalTrials.gov | 15 | 14 | https://conductscience.org/library/drugs?q=MONDO_0004981 |
| Premature ventricular contraction | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=HP_0006682 |
| Supraventricular tachycardia | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=HP_0004755 |
| narcolepsy | Phase 2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0021107 |
| ventricular ectopy | Unknown | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=EFO_0009276 |
| Andersen-Tawil syndrome | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0008222 |
| Parkinson disease | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005180 |
| Ventricular arrhythmia | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0004308 |
| arrhythmogenic right ventricular cardiomyopathy | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0016587 |
| atrial flutter | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005310 |
1 to 10 of 18Source Open Targets
See all 18 diseasesTrials44
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00523978 | A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation | Phase 3 | 245 | 2012-08-28 | flecainide | Its name | ClinicalTrials.gov |
| NCT00408200 | A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation | 110 | 2013-03-07 | flecainide | Its name | ClinicalTrials.gov | |
| NCT03624920 | Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness | Phase 2 | 77 | 2020-12-01 | THN102 | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT02821715 | Safety and Efficacy of THN102 on Sleepiness in Narcoleptic Patients | Phase 2 | 51 | 2020-09-04 | flecainide | Its name | ClinicalTrials.gov |
| NCT03685149 | Pilot Randomized Trial With Flecainide in ARVC Patients | Phase 2 | 22 | 2024-08-20 | flecainide | Its name | ClinicalTrials.gov |
| NCT01117454 | Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia | 14 | 2017-05-17 | flecainide | Its name | ClinicalTrials.gov | |
| NCT01833455 | Premature Ventricular Contractions (PVCs) and Blood Pressure Control | Phase 2 | 8 | 2019-02-22 | flecainide | Its name | ClinicalTrials.gov |
| NCT07270848 | Dronedarone Rhythm Intervention for Early Atrial Fibrillation | Phase 4 | 1,898 | flecainide | Its name | ClinicalTrials.gov | |
| NCT07405671 | Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation | Phase 4 | 988 | flecainide | Its name | ClinicalTrials.gov | |
| NCT00215774 | Flecainide-Short Long Study (Flec-SL) | 760 | flecainide | Its name | ClinicalTrials.gov |
1 to 10 of 44
See all 44 trialsComparisons in its trials13
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Cryoablation vs Standard Treatment With Drugs Only: Freedom From Major Atrial Fibrillation Events (MAFEs) | 158 of 163 | 75 of 82 | 245 | NCT00523978 | Trial comparisons |
| Cryoablation vs Standard Treatment With Drugs Only: Treatment Success | 114 of 163 | 6 of 82 | 245 | NCT00523978 | Trial comparisons |
| Cryoablation vs Standard Treatment With Drugs Only: Freedom From Chronic Treatment Failure (CTF) | 117 of 163 | 6 of 82 | 245 | NCT00523978 | Trial comparisons |
| Cryoablation vs Standard Treatment With Drugs Only: serious adverse events | 20 of 163 | 12 of 82 | 245 | NCT00523978 | Trial comparisons |
| AAD:NO vs AAD:YES: Freedom From Atrial Arrhythmia at 6 Months Post Procedure. | 39 of 57 | 35 of 53 | 110 | NCT00408200 | Trial comparisons |
AAD:NO vs AAD:YES: Composite Endpoint: Atrial Arrhythmias Lasting >24 Hrs or Requiring Antiarrhythmic Drug Therapy; Need for Cardioversion/Repeat Ablation During the Study Period; Adverse Outcome/Intolerance of Antiarrhythmic Agent Requiring Cessation or Change of Drug | 24 of 57 | 10 of 53 | 110 | NCT00408200 | Trial comparisons |
| AAD:NO vs AAD:YES: serious adverse events | 0 of 57 | 0 of 53 | 110 | NCT00408200 | Trial comparisons |
| Flecainide vs Placebo: deaths from any cause | 0 of 22 | 0 of 22 | 44 | NCT03685149 | Trial comparisons |
| Flecainide vs Placebo: serious adverse events | 1 of 22 | 1 of 22 | 44 | NCT03685149 | Trial comparisons |
| Flecainide vs Placebo: Number of Participants With Proarrhythmic Response to Flecainide | 3 of 19 | 3 of 19 | 38 | NCT03685149 | Trial comparisons |
1 to 10 of 13
See all 13 comparisons in its trialsPapers from its trials25
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials6
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Card Sorting Test (Berg) | 1 | 0 | ConductCognition |
| Go/No-Go Task | 1 | 0 | ConductCognition |
| 2-Back Task | 1 | 0 | ConductCognition |
| Psychomotor Vigilance Task | 1 | 1 | ConductCognition |
| Trail Making Test A | 1 | 0 | ConductCognition |
| Trail Making Test B | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL652
GET https://conductscience.org/api/drugs/v1/CHEMBL652/trials?page=2